Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naldebain and SafeTynadol for post-knee replacement pain
NCT05842733Phase 2Unknown
- Sponsor
- Sinew Pharma
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dinalbuphine sebacate, SNP-810 in postoperative pain, sponsored by Sinew Pharma. Status: unknown.
02
Drugs
dinalbuphine sebacateSNP-810
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05842733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842733.